Clinical Trials Logo

Clinical Trial Summary

Genetic variations, i.e. polymorphisms, may be associated with gender dysphoria, e.g. transsexualism. This study aims to identify such variations.


Clinical Trial Description

Context: Early developmental exposure of the brain to sex steroids may play a role in the etiology of transsexualism.

Objective: To assess the association between transsexualism and allele and genotype frequencies of the steroid 5-alpha reductase (SRD5A2) Val89Leu polymorphism.

Design and Patients: We performed a case-control study of 100 male-to-female (MtF) transsexuals, 47 female-to-male (FtM) transsexuals, 755 male controls, and 915 female controls. DNA was extracted from buccal swabs and genotypes were determined by polymerase chain reaction.

Results: SRD5A2 Val89Leu allele frequencies (SRD5A2 V: 137/200 [69%] and SRD5A2 L: 63/200 [31%] vs. SRD5A2 V: 1065/1510 [71%] and SRD5A2 L: 445/1510 [29%], respectively; p=0.6; Odds Ratio [OR] 1.10; 95% Confidence Interval [CI] 0.76-1.58) and genotype distributions (SRD5A2 V/V+V/L: 92/100 [92%] and L/L 8/100 [8%] vs. SRD5A2 V/V+V/L: 683/755 [91%] and L/L 72/755 [9%], respectively, p=0.7; OR 0.82; 95% CI 0.24-2.84) were not significantly different between MtF transsexuals and male controls. SRD5A2 Val89Leu allele frequencies (SRD5A2 V: 70/94 [74%] and SRD5A2 L: 24/94 [26%] vs. SRD5A2 V: 1253/1830 [69%] and SRD5A2 L: 573/1830 [31%], respectively; p=0.3; OR 0.75; 95% CI 0.45-1.26) and genotype distributions (SRD5A2 V/V+V/L: 44/47 [93%] and L/L 3/47 [7%] vs. SRD5A2 V/V+V/L: 823/915 [90%] and L/L 92/915 [10%], respectively, p=0.6; OR 0.61; 95% CI 0.11-3.32) were also not significantly different between FtM transsexuals and female controls. Of note, there was no gender-specific genotype distribution among controls.

Conclusions: The SRD5A2 Val89Leu polymorphism is not associated with transsexualism and is no candidate gene of this condition. ;


Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00435513
Study type Observational
Source Medical University of Vienna
Contact
Status Completed
Phase Phase 0
Start date March 2007
Completion date July 2008

See also
  Status Clinical Trial Phase
Recruiting NCT05487794 - Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis N/A
Completed NCT02185274 - Observational Study on Metabolism and Psychopathology in Transsexual Patients
Recruiting NCT04838249 - Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System
Completed NCT00146146 - Testosterone and Its Metabolites in GID Phase 3
Completed NCT04864951 - HPV Prevalence in Transpersons - a Prospective Study N/A
Completed NCT04290286 - i2TransHealth: Interdisciplinary, Internet-based Trans Health Care N/A
Recruiting NCT03637920 - Sexuality in Transmen During Hormone and Operative Treatment
Completed NCT03823014 - Use of an External Erectile Device in Transgender Man Following Phalloplasty N/A
Recruiting NCT03872648 - TransCare - Genital Surgery for Trans Women in Centralized vs. Decentralized Health Care Delivery Settings
Completed NCT01065220 - Sex Steroids and the Serotonin Transporter Phase 4
Enrolling by invitation NCT03595956 - Transgender Cohort Study of Gender Affirmation and HIV-related Health
Completed NCT02119377 - First Australian National Trans Mental Health Study N/A
Completed NCT02518009 - GEnder Dysphoria Treatment in Sweden
Completed NCT00135148 - Decrease of Libido of Post-Operative Male-Female Transsexuals and a Healthy Female Control Group N/A